Assertio Holdings, Inc.

NASDAQ:ASRT

Drug Manufacturers - Specialty & Generic

Healthcare
$23.50 +0.04%

+$0.01 today

Market cap
$151.86M
Beta
0.53
P/E (TTM)
-4.2
EPS (TTM)
-$5.55
52W Low $8.61High $23.50

Volume 0.27M

Average 0.33M

ASRT Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Assertio Holdings, Inc.NASDAQ: ASRT

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $5.84M fell 37.0% year over year, behind the -9.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -3.5% a year.

Context

  • Depreciation & amortization amounted to 25.3% of revenue in FY2025, up 4.6 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -37.0% toward the trailing-twelve-month pace of -9.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.84M+0.0% QoQ
Last fiscal yearDec 2025
$30.01M+16.2% YoY
LTMMar 2026
$26.58M-9.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.0%——
1 year+16.2%——
3-year CAGR-3.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
30.01M USD
Year-over-year change
+16.2%
4-year CAGR
+0.8%

Depreciation & Amortization vs competitors

How ASRT compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.6% is the 4th highest of 10, against a peer median of -11.3%.
  • Depreciation & amortization amounts to 26.0% of revenue for ASRT, versus a peer median of 5.6%.
ASRT Competitors
Depreciation & Amortization for ASRT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ASRTAssertio Holdings, Inc.LTM Mar 2026$26.58M USD-9.6%-3.5%26.0%
INCRInterCure Ltd.LTM Jun 2025₪8.45M ILS+33.4%+13.6%3.5%
VXRTVaxart, Inc.LTM Mar 2026$7.74M USD-13.3%+13.9%3.0%
FBIOFortress Biotech, Inc.LTM Mar 2026$5.17M USD+4.4%-20.7%7.8%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$2.88M USD-18.4%-17.7%31.5%
XBITXBiotech Inc.LTM Mar 2026$1.58M USD-10.2%-13.6%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$1.21M USD+8.3%+36.2%—
LUNGPulmonx CorporationLTM Mar 2026$1.2M USD-11.3%-33.9%1.4%
NTRBNutriband Inc.LTM Apr 2026$170.49K USD-37.6%-19.3%9.5%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$131K USD-84.0%-41.1%—
Peer median (excluding ASRT) —-11.3%-17.7%5.6%

Competitors are the stored peer set for ASRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.28M)109.63M(331.94M)(21.58M)(30.38M)
Depreciation & Amortization29.08M33.4M28.23M25.83M30.01M
Deferred Income Tax0(80.38M)76.2M00
Stock-Based Compensation3.55M7.5M9.16M5.01M3.45M
Change in Working Capital(31.29M)(13.01M)140K5.2M(45.33M)
Accounts Receivables(11K)(996K)48.67M(6.46M)(65.99M)
Inventory4.27M(6.59M)(4.97M)(9.58M)9.68M
Accounts Payables(28.7M)(10.11M)(29.35M)(1.26M)(13.29M)
Other Working Capital(6.85M)4.69M(14.21M)22.5M24.27M
Other Non-Cash Items5.48M21.46M267.82M11.95M14.07M
Operating Cash Flow5.52M78.6M49.6M26.41M(28.18M)
Capital Expenditures(53K)(274K)(628K)00
Acquisitions (Net)(18.47M)(42.4M)1.53M00
Purchases of Investments000(98.61M)(119.2M)
Sales of Investments002.19M49.69M115.38M
Other Investing Activities0000(8.17M)
Investing Cash Flow(18.53M)(42.67M)3.1M(48.91M)(11.99M)
Debt Repayment(9.84M)(750K)(10.5M)00
Common Stock Issued44.86M7.02M000
Common Stock Repurchased(418K)(838K)(7.9M)(350K)0
Dividends Paid00000
Other Financing Activities(5.58M)(13.23M)(25.8M)0(189K)
Financing Cash Flow29.03M(7.79M)(44.2M)(350K)(189K)
Effect of Forex Changes00000
Net Change in Cash16.02M28.13M8.5M(22.85M)(40.36M)
Free Cash Flow5.47M78.32M48.98M26.41M(28.18M)

Assertio Holdings, Inc.

NASDAQ:ASRT

Intrinsic Alpha fair value

Locked

Current Price

$23.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.